Skip to main content
Fig. 5 | Military Medical Research

Fig. 5

From: Excellent effects and possible mechanisms of action of a new antibody–drug conjugate against EGFR-positive triple-negative breast cancer

Fig. 5

Therapeutic efficacy of LR004-VC-MMAE against TNBC in vivo. a Growth curves of MDA-MB-468 and MDA-MB-231 cell-derived xenograft tumors. Mice were inoculated with MDA-MB-468 or MDA-MB-231 cells and treated with PBS (control), naked antibody LR004 (10 mg/kg), doxorubicin (positive control, 2 mg/kg) or LR004-VC-MMAE (10 mg/kg) every 4 days via the tail vein for a total of four injections (n = 6). b Body weight curves of mice in (a)

Back to article page

Military Medical Research

ISSN: 2054-9369